Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ARS Pharmaceuticals (SPRY) Accounts Payables: 2021-2025

Historic Accounts Payables for ARS Pharmaceuticals (SPRY) over the last 5 years, with Sep 2025 value amounting to $49.8 million.

  • ARS Pharmaceuticals' Accounts Payables rose 201.24% to $49.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $49.8 million, marking a year-over-year increase of 201.24%. This contributed to the annual value of $22.8 million for FY2024, which is 960.40% up from last year.
  • As of Q3 2025, ARS Pharmaceuticals' Accounts Payables stood at $49.8 million, which was up 12.43% from $44.3 million recorded in Q2 2025.
  • ARS Pharmaceuticals' 5-year Accounts Payables high stood at $49.8 million for Q3 2025, and its period low was $126,000 during Q3 2022.
  • For the 3-year period, ARS Pharmaceuticals' Accounts Payables averaged around $18.5 million, with its median value being $10.9 million (2023).
  • Per our database at Business Quant, ARS Pharmaceuticals' Accounts Payables crashed by 92.67% in 2022 and then skyrocketed by 8,586.51% in 2023.
  • Quarterly analysis of 5 years shows ARS Pharmaceuticals' Accounts Payables stood at $3.1 million in 2021, then soared by 58.71% to $4.9 million in 2022, then tumbled by 56.32% to $2.2 million in 2023, then surged by 960.40% to $22.8 million in 2024, then surged by 201.24% to $49.8 million in 2025.
  • Its last three reported values are $49.8 million in Q3 2025, $44.3 million for Q2 2025, and $27.0 million during Q1 2025.